https://www.selleckchem.com/products/AT9283.html
Background High mobility group box 1 (HMGB1)-receptor for advanced glycation endo-products (RAGE) axis serves as a key player in linking inflammation and carcinogenesis. Recently, papaverine was revealed to suppress the HMGB1-RAGE inflammatory signaling pathway and cancer cell proliferation. Therefore, a dual suppressor targeting this axis is expected to become a new type of therapeutic agent to treat cancer. Methods Papaverine 3D pharmacophore mimetic compounds were selected by the LigandScout software from our in-house, anti-cancer che
Giống
Bình luận
Đăng lại
